The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > LATEST
LATEST
-
BUSINESS Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
-
BUSINESS Novel β-Lactamase Inhibitor Nacubactam Safe and Effective: Meiji
March 17, 2025
-
BUSINESS AbbVie Files Migraine Med Atogepant in Japan
March 17, 2025
-
REGULATORY MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
-
REGULATORY PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
March 17, 2025
-
BUSINESS Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
-
BUSINESS Jiho Survey Finds Improvement in Price Revision Rates for Generic Players
March 17, 2025
-
BUSINESS AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies
February 7, 2025
-
BUSINESS MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting
January 24, 2025
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…